PHARMA NEWS, MULTICHANNEL & CROSSCHANNEL MAKETING
282.2K views | +4 today
Follow

Sanofi et Bpifrance veulent booster le développement de la e-santé en France  #hcsmeufr #esante

From www.challenges.fr

Doper l’innovation en santé en faisant collaborer start-up et grands groupes.

Avec deux initiatives très différentes, c’est un message très similaire qu’ont envoyé ce lundi 4 décembre Sanofi et Bpifrance.

Le plus gros laboratoire français inaugurait sur son campus de Gentilly, dans le Val de Marne,  le "39 bis", un laboratoire entièrement dédié à la e-santé.

De son côté, la banque publique des PME lançait le Health Tech Hub, un programme d’accélération pour ses participations dans le secteur médical.  

Chez Sanofi, la volonté d’accélérer dans la santé connectée se traduit par le lancement du "39 bis", un espace de 170 m2 dédié à la e-santé, sur son campus de Gentilly.

Un lieu qui entend répondre à "une volonté farouche de capitaliser sur l’extraordinaire écosystème de la santé en France, et particulièrement de la e-santé", a souligné Guillaume Leroy, président de Sanofi France.

Axé sur l’usage des données numériques au profit des patients et des professionnels de santé, ce lieu illustre l’effort "d’innovation ouverte" revendiqué par le laboratoire français ...

France Silver Eco's curator insight, December 6, 7:29 AM

Alors que Sanofi lance un nouvel espace dédié à l’usage des données numériques au profit des patients et des professionnels de santé, Bpifrance dévoile un nouveau dispositif d'accompagnement pour les start-up dans la e-santé.

Ensemble, améliorons l’information, la prévention et la prise en charge des maladies infectieuses. #fsp2017 #hcsmeufr

From storify.com

Ensemble, améliorons l’information, la prévention et la prise en charge des maladies infectieuses.
#fsp2017 - Campus Sanofi Val de Bièvre - 1er Décembre 2017

No comment yet.

Comment Amazon et Uber veulent changer la logistique (infographie)   #esante #hcsmeufr #digitalhealth 

From realitesroutieres.fr

Amazon et Uber ne sont pas que de simples sites internet ou applications mobiles, ce sont de grandes multinationales qui investissent à coup de milliards de dollars dans des startups innovantes. Leur but : réduire les coûts de transport en passant notamment par une automatisation massive.
No comment yet.

Pharma should avoid Facebook at all costs #esante #hcsmeufr #digitalhealth #mhealth

From worldofdtcmarketing.com

Facebook’s objective was to keep users addicted to social media as much as possible, but now that Facebook has become nothing but a media company they don’t want to play by the same rules as other media companies.  The risks of advertising on Facebook are too great while the rewards are too few.

In the early days of social media, and Facebook, both social media experts and Facebook told the marketers they “had to be on Facebook”.  Then organic reach dropped to below 1% and Facebook told us again that we had to be on the site as advertisers.  Brands flocked to social media, but Facebook said that it had messed up more ad metrics than previously thought, potentially eroding its trust and relationship with marketers and publishers.  The social network said in a blog postmiscalculated it the number of completed video views, the total organic reach for business Pages and the amount of time spent with Instant Articles.

 Time and time again Facebook has undermined its credibility by making claims that are easily proven to be false, and then defended these claims with statements that are absurd.   It was reported, for example,  that Facebook was claiming to reach 41 million Americans between the ages of 18-24. If Facebook reached every American between 18 and 24 they’d still be 10 million short. There are only 31 million of them.

Even P&G, that huge marketing powerhouse, is pulling back on Facebook.  According to the Wall Street Journal “Procter & Gamble Co., the biggest advertising spender in the world, will move away from advertising on Facebook Inc. that targets specific consumers after deciding the practice has limited effectiveness”.

When Congress wanted to talk with social media executives they sent their lawyers instead.  In a speech on Wednesday, Senator Franken offered up a damning critique of the companies, charging them with having unchecked influence that even they don’t know how to control. “These companies may not be up to the challenge that they’ve created for themselves,” he said.

So how can pharma really use Facebook and be confident that their posts are not going to be avoided or used in other fake news?   When it comes down to it the best way to increase the effectiveness of your digital ads is through better creative based on user studies and testing.

The social media boat sailed a long time, largely without pharma.  Their fears over social media use may have been too extreme, but in the end their fear is justified for another reason.

No comment yet.

Eisai launches location tracker for dementia patients  #esante #hcsmeufr #digitalhealth

From www.pmlive.com

Eisai has launched a tracking tool in Japan for people with dementia and the elderly.

The firm has teamed up with Japanese smartphone app network Mamorio to launch Me-Mamorio, a lightweight button-shaped tag that uses Bluetooth to communicate positional data.

Small enough to be sewn into a jacket or hat or attached to a bag or wallet, Me-Mamorio’s data can then be accessed by family members or care workers.

The wearable’s launch is being bolstered by a further collaboration with insurance company Tokio Marine Group to offer services such as a 24-hour emergency medical advice telephone hotline.

Japan’s National Police Agency has seen year-on-year increases in the number of missing persons who also have dementia since starting to track the figures five years ago, and in 2016 registered 15,432 such cases.

Meanwhile, it is estimated that by 2025 one in five people aged 65 or over in the country will suffer from dementia.
No comment yet.

GSK boosts medtech firm Owlstone with use of ‘Breath Biopsy’ in respiratory trial  #esante #hcsmeufr #digitalhealth

From pharmaphorum.com

One of the UK’s most promising medtech start-ups, Owlstone Medical has been given a major boost by GSK’s decision to include its technology in a major clinical trial programme.

Cambridge-based Owlstone is developing the Breath Biopsy which it believes could help diagnose a huge range of diseases, including lung, bladder and breast cancer, simply from biomarker compounds present in the breath of patients.

The start-up has already begun a major trial to test the accuracy and reliability of the device in cancer detection in partnership with Cancer Research UK.

But now the new partnership with GSK in respiratory clinical trials provides an additional boost of confidence in the technology. It will also give Owlstone a new income stream, although the companies haven’t disclosed details of the deal.

GSK is a lead player in the respiratory medicines field, and will incorporate the Breath Biopsy platform into phase 2 clinical trials of danirixin, one of the GSK’s novel respiratory pipeline candidates.

Breath Biopsy will be used to assess whether the right patient for the right treatment can be identified, as well as assessing the treatment effects of a novel drug for chronic obstructive pulmonary disease (COPD). The technology works by capturing Volatile Organic Compounds (VOCs) in breath completely non-invasively, and analyse them with high sensitivity.

The promise of the Breath Biopsy device therefore, is that it could help GSK identify sub-populations who respond best to the treatment, allowing it to shape its clinical trial programme and potentially improving chances of developing a highly effective, marketable drug.
No comment yet.

Comment mieux lutter contre les maladies infectieuses ? #FSP2017 #hcsmeufr

From pharmageek.fr

Pour sa 11eme édition le FORUM SANTE PUBLIQUE SANOFI s'intéresse à la lutte contre les maladies infectieuses et à l'antibioresistance.
No comment yet.

Médicament connecté : une pilule dure à faire passer ? #hcsmeufr #esante #pharma #digitalhealth

From pharmageek.fr

Le premier médicament connecté vient d'être autorisé par la FDA. Entre espoirs et inquiétudes, quelles sont les enseignements à tirer ?
No comment yet.

Health and life science supply chain markets "ripe for digital disruption" #pharma #esante #hcsmeufr #digitalhealth

From www.supplychaindigital.com

All signs are that the life sciences and healthcare market is ripe for disruption, with ecommerce coming into its own in the sector. 
No comment yet.

Welcome to Ieso Digital Health | Ieso Digital Health | United Kingdom

From www.iesohealth.com

Ieso Digital Health provides online cognitive behaviour therapy to treat a range of mental health conditions on behalf of health providers (including the NHS) private individuals and businesses. - Ieso Digital Health United Kingdom
No comment yet.

US regulators approve first digital pill to track patients #esante #hcsmeufr #digitalhealth

From www.abc.net.au

A drug with a tiny digestible sensor that tells doctors, carers or family if a patient has taken their medication has been approved in the US. But should it be used in Australia?
No comment yet.

The future for pharma marketing is personal

From pharmaphorum.com

With marketing a consistent issue for pharma, one which will likely continue to grow, getting personal is the only option for future success.
No comment yet.

Where is Pharma Marketing Headed in 2018?

From mobilemarketingwatch.com

This week, MMW was privy to some insights on the future of pharma marketing from Sloan Gaon, CEO of PulsePoint. So what’s ahead in the new year? Here are some of Goan’s predictions: AI and ML will save lives in 2018 AI and ML will revolutionize clinical trial recruitment by finding patients based on a …
No comment yet.

Clinical trial? There’s an app for that #esante #hcsmeufr #digitalhealth

From www.oreilly.com

When the Cleveland Clinic was looking for participants in its more than 130 cancer trials, its outreach teams didn’t just cold-call doctors and hospitals. They tried something new: they launched an app. The Cancer Trial App is designed for two distinct populations: patients looking for clinical trials and doctors who are treating those patients. Users who download the app either on iOS or Android receive information on trials by disease, phase, physician, and hospital location. In addition, the app details each trial’s objective, eligibility rules, and progress.

The Cleveland Clinic’s app is a simple solution to a complex problem: how to make clinical trials easier for individuals to participate in. Because of a lack of vendors, complex regulatory tools, and institutional inertia, many of the digital workflow and recordkeeping tools that are commonplace in other parts of biology never made it to clinical trials.

According to Premier Research, a life sciences consulting firm, only several hundred of the more than 150,000 mobile health applications published as of December 2016 focus on clinical trials. And of those, most are directory apps like the Cleveland Clinic’s, rather than more complicated apps that enhance the patient experience.
No comment yet.

Digital Transformation Opportunities in Healthcare Market insights to 2022 Focusing on key players like SAP AG, IBM Corporation, Oracle Corporation, Google, Inc., Dell EMC, Adobe Systems, Hewlett-P...

From www.medgadget.com

Digital health has turned into a popular expression with expanding arrangement of digital health stages, for example, telehealth, versatile health and diff
No comment yet.

A quelques semaines du PLFSS, le Leem dresse l'état des lieux de l'industrie pharma #hcsmeufr #esante #pharma

From www.usinenouvelle.com

"Un retour de la croissance en trompe-l'oeil". Alors que le marché pharmaceutique français renoue avec la croissance, les entreprises du... - L'Usine Santé
No comment yet.

How the Diabetes Community is Revolutionising and Democratising Self-care #esante #hcsmeufr #digitalhealth

From www.thejournalofmhealth.com

As the world reflects on diabetes and the highly complex global challenges it poses, it’s interesting to explore the role the diabetes community has played in revolutionising and democratising self-care; creating an inspiring blueprint for how we might manage other chronic conditions.

The diabetes community has been pioneering in embracing the benefits of self-management. The early adoption of mHealth applications have played a key role in helping patients and clinicians collect and share information and learn more about their conditions.

The clinical benefits of putting testing in the hands of patients has been obvious for many years. Since the early electrochemical glucose meters in the late ’80s and early ’90s functionality to store and track trends has been added to patients’ home glucose monitors.

Bluetooth, USB and other connectivity including capturing the results direct from the screen has become increasingly common with a number of diabetes data management systems, such as CareLink and mySugr evolving to support patients in tracking their results and medication. Those tools are increasingly looking to add additional inputs and AI (artificial intelligence) to provide decision-making support – as seen with Glooko.

No comment yet.

Infographic: Pharma customer engagement missing the mark with physicians #hcsmeufr #esante #digitalhealth

From www.drgdigital.com

The good news is that there's lots of opportunities to differentiate from competitors on delivering a better experience.
Guillermo Grosso's curator insight, November 24, 9:34 AM

Infographic: Pharma customer engagement missing the mark with physicians #hcsmeufr #esante #digitalhealth

Big Pharma Racks Up Facebook Likes But Not So Much from Patients

From www.pharma-mkting.com

In this 2.5-minute audio snippet, Pharmaguy contemplates how big drug companies can get hundreds of thousands of 'likes' on Facebook but score very low among patient groups worldwide. Only 25% of patients, for example, think pharma marketing is ethical. A case in point is Low-T direct-to-consumer advertising.

 

Listen here.

No comment yet.

Unicancer s'allie avec AstraZeneca pour construire une base de données sur le cancer du poumon #hcsmeufr #esante

From www.ticpharma.com

PARIS, COURBEVOIE (Hauts-de-Seine) (TICpharma) - La fédération des centres de lutte contre le cancer (CLCC) Unicancer et le laboratoire AstraZeneca ont annoncé le 6 novembre dans un communiqué la signature d'un nouveau partenariat pour rassembler des données de vie réelle dans le cancer du poumon.


No comment yet.

Johnson & Johnson launches surgery patient support platform #esante #hcsmeufr #digitalhealth

From www.mobihealthnews.com

Johnson & Johnson has announced a suite of digital tools designed for patients preparing to undergo or recovering from knee, hip, and weight loss surgery.

No comment yet.

Le CDO de Merck KGaA pointe les frictions entre industries de santé et entreprises de la tech #esante #hcsmeufr 

From www.ticpharma.com

BERLIN (TICpharma) - Le secteur de la santé est dominé par des structures très traditionnelles qui se retrouvent de plus en plus confrontées à l'agilité des entreprises spécialisées dans les technologies se frayant un chemin vers le marché, a analysé James Kugler, Chief Digital Officer (CDO) du groupe allemand Merck KGaA, dans un entretien accordé à APM Health Europe.


No comment yet.